Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR.

Arch Gen Psychiatry. 2011 Jan;68(1):71-8. doi: 10.1001/archgenpsychiatry.2010.116. Epub 2010 Sep 6.

PMID:
20819978
2.

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ.

J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13.

PMID:
25586396
3.

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX.

Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010. Epub 2014 Apr 26.

PMID:
24882567
4.

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL.

J Clin Psychiatry. 2006 Nov;67(11):1735-40.

PMID:
17196053
5.

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

Studerus E, Kometer M, Hasler F, Vollenweider FX.

J Psychopharmacol. 2011 Nov;25(11):1434-52. doi: 10.1177/0269881110382466. Epub 2010 Sep 20.

PMID:
20855349
6.

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Garcia-Romeu A, Griffiths RR, Johnson MW.

Curr Drug Abuse Rev. 2014;7(3):157-64.

7.

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R.

Psychopharmacology (Berl). 2011 Dec;218(4):649-65. doi: 10.1007/s00213-011-2358-5. Epub 2011 Jun 15.

8.

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR.

J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.

9.

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA.

J Psychopharmacol. 2016 Dec;30(12):1181-1197.

10.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL.

J Psychopharmacol. 2016 Dec;30(12):1165-1180.

11.

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Griffiths RR, Richards WA, McCann U, Jesse R.

Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. Epub 2006 Jul 7.

PMID:
16826400
12.

The Heffter Research Institute: past and hopeful future.

Nichols DE.

J Psychoactive Drugs. 2014 Jan-Mar;46(1):20-6.

PMID:
24830182
13.

Effect of laughter yoga on mood and heart rate variability in patients awaiting organ transplantation: a pilot study.

Dolgoff-Kaspar R, Baldwin A, Johnson MS, Edling N, Sethi GK.

Altern Ther Health Med. 2012 Sep-Oct;18(5):61-6. Erratum in: Altern Ther Health Med. 2012 Nov-Dec;18(6):79.

PMID:
22894892
14.

Effects of psilocybin on time perception and temporal control of behaviour in humans.

Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX.

J Psychopharmacol. 2007 Jan;21(1):50-64. Epub 2006 May 19.

PMID:
16714323
15.

Effect of laughter on mood and heart rate variability in patients awaiting organ transplantation: a pilot study.

Dolgoff-Kaspar R, Baldwin A, Johnson S, Edling N, Sethi GK.

Altern Ther Health Med. 2012 Jul-Aug;18(4):53-8.

PMID:
22891377
16.

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Johnson MW, Sewell RA, Griffiths RR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):132-40. doi: 10.1016/j.drugalcdep.2011.10.029. Epub 2011 Nov 29.

17.

Return of a problem child.

Stix G.

Sci Am. 2009 Oct;301(4):18, 20. No abstract available.

PMID:
19780439
18.

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Griffiths R, Richards W, Johnson M, McCann U, Jesse R.

J Psychopharmacol. 2008 Aug;22(6):621-32. doi: 10.1177/0269881108094300. Epub 2008 Jul 1.

19.

Psilocybin--summary of knowledge and new perspectives.

Tylš F, Páleníček T, Horáček J.

Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. doi: 10.1016/j.euroneuro.2013.12.006. Epub 2013 Dec 17. Review.

PMID:
24444771
20.

Hallucinogens as medicine.

Griffths RR, Grob CS.

Sci Am. 2010 Dec;303(6):76-9. No abstract available.

PMID:
21141361

Supplemental Content

Support Center